STAT

LISTEN: Biotech’s six months of surprise, the shaky road ahead, and sell-side self-doubt

Why is everyone so down on biotech's household names? And if a stock gets downgraded in an analyst note, should anyone care? Find out on "The Readout LOUD."

Why is everyone so down on biotech’s household names? How do you become a day trader? And if a stock gets downgraded in

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Opinion: Virtual And Augmented Reality Can Save Lives By Improving Surgeons’ Training
Rapid advances in the development of medical devices in the 21st century are contributing to healthier lives, but bring with them a new challenge: teaching clinicians how to use these often-complicated technologies. Teaching them poorly, or failing t
STAT4 min readPolitics
Alzheimer’s Advocates Are Swarming The Iowa State Fair, Pushing Politicians To Consider Policies To Fight The Disease
Amid the butter sculptures and the fried oreos, politicians in Iowa must face Alzheimer’s advocates who want to put them on the record about a plan for fighting the disease.
STAT7 min read
Opinion: Novartis Violated FDA’s Sacred Principle: In God We Trust, All Others Must Bring Data
My experience in more than 40 years of developing and evaluating medical products, and two years working at the FDA, has convinced me that it's essential to have a second…